BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27170161)

  • 1. Investigational new drugs for brain cancer.
    Staedtke V; Bai RY; Laterra J
    Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy in brain tumors: a new target for therapeutic intervention.
    Kaza N; Kohli L; Roth KA
    Brain Pathol; 2012 Jan; 22(1):89-98. PubMed ID: 22150924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.
    Chelliah SS; Paul EAL; Kamarudin MNA; Parhar I
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33671796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.
    Okosun J; Packham G; Fitzgibbon J
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1321-32. PubMed ID: 24855903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
    Skouras P; Markouli M; Strepkos D; Piperi C
    Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Targeting of Altered Metabolism in High-Grade Glioma.
    Scott AJ; Lyssiotis CA; Wahl DR
    Cancer J; 2021 Sep-Oct 01; 27(5):386-394. PubMed ID: 34570453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.
    Das A; Fernandez NR; Levine A; Bianchi V; Stengs LK; Chung J; Negm L; Dimayacyac JR; Chang Y; Nobre L; Ercan AB; Sanchez-Ramirez S; Sudhaman S; Edwards M; Larouche V; Samuel D; Van Damme A; Gass D; Ziegler DS; Bielack SS; Koschmann C; Zelcer S; Yalon-Oren M; Campino GA; Sarosiek T; Nichols KE; Loret De Mola R; Bielamowicz K; Sabel M; Frojd CA; Wood MD; Glover JM; Lee YY; Vanan M; Adamski JK; Perreault S; Chamdine O; Hjort MA; Zapotocky M; Carceller F; Wright E; Fedorakova I; Lossos A; Tanaka R; Osborn M; Blumenthal DT; Aronson M; Bartels U; Huang A; Ramaswamy V; Malkin D; Shlien A; Villani A; Dirks PB; Pugh TJ; Getz G; Maruvka YE; Tsang DS; Ertl-Wagner B; Hawkins C; Bouffet E; Morgenstern DA; Tabori U
    Cancer Discov; 2024 Feb; 14(2):258-273. PubMed ID: 37823831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas.
    Kolsteeg C; Hulleman E; Bianco J
    Br J Cancer; 2022 Oct; 127(7):1193-1200. PubMed ID: 35715639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications associated with immunotherapy for brain metastases.
    Tran TT; Jilaveanu LB; Omuro A; Chiang VL; Huttner A; Kluger HM
    Curr Opin Neurol; 2019 Dec; 32(6):907-916. PubMed ID: 31577604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Insight on Skin Cancer About Different Targets With Update on Clinical Trials and Investigational Drugs.
    Vishwas S; Paul SD; Singh D
    Curr Drug Deliv; 2024; 21(6):852-869. PubMed ID: 37496132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
    Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
    J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations when treating high-grade pediatric glioma patients with immunotherapy.
    Crotty E; Downey K; Ferrerosa L; Flores C; Hegde B; Raskin S; Hwang E; Vitanza N; Okada H
    Expert Rev Neurother; 2021 Feb; 21(2):205-219. PubMed ID: 33225764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic treatment of adult gliomas: a narrative review].
    Mangel L
    Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.
    Ellingson BM; Wen PY; Cloughesy TF
    Cancer J; 2021 Sep-Oct 01; 27(5):395-403. PubMed ID: 34570454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of targeted new agents to improve the outcome for children with leukemia.
    Bautista F; Van der Lugt J; Kearns PR; Mussai FJ; Zwaan CM; Moreno L
    Expert Opin Drug Discov; 2016 Nov; 11(11):1111-1122. PubMed ID: 27670965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment advances in high-grade gliomas.
    Chen X; Cui Y; Zou L
    Front Oncol; 2024; 14():1287725. PubMed ID: 38660136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NanoNail Gives Drug Response Readouts In Situ.
    Cancer Discov; 2023 Nov; 13(11):2297-2298. PubMed ID: 37703445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging and investigational therapies for neuroblastoma.
    Applebaum MA; Desai AV; Glade Bender JL; Cohn SL
    Expert Opin Orphan Drugs; 2017; 5(4):355-368. PubMed ID: 29062613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on current and emerging treatment options for glioma: A comprehensive review.
    Lucke-Wold B; Rangwala BS; Shafique MA; Siddiq MA; Mustafa MS; Danish F; Nasrullah RMU; Zainab N; Haseeb A
    World J Clin Oncol; 2024 Apr; 15(4):482-495. PubMed ID: 38689623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma-on-a-Chip Models.
    Ustun M; Rahmani Dabbagh S; Ilci IS; Bagci-Onder T; Tasoglu S
    Micromachines (Basel); 2021 Apr; 12(5):. PubMed ID: 33926127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.